At a glance
ClinicalIndex Comparison RecordPhase 3Not Yet Recruiting· 231 target
Drug / intervention
MRG004A plus best supportive care +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multi-center, Phase III Study of MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer
In Brief
A Phase 3 clinical trial evaluating MRG004A plus best supportive care and Placebo plus best supportive care for Advanced Pancreatic Cancer. Not yet recruiting, targeting 231 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, multi-center, phase III study to evaluate the efficacy and safety, pharmacokinetic profile and immunogenicity of MRG004A in patients with advanced pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Pancreatic Cancer
CountriesChina
Collaborators--
Timeline
Phase 3Not Yet Recruiting
20262027
First PostedAug 2025
TodayJul 2026
Enrollment StartJan 2027
Primary CompletionJun 2027
First PostedAug 24, 2025
Enrollment StartJan 1, 2027
Primary CompletionJun 1, 2027
TodayJul 1, 2026
Enrollment to primary: 5 monthsPosted 10 months agoPrimary completion in 11 months
Interventions
MRG004A plus best supportive caredrug
MRG004A will be administrated as specified in the protocol.
Placebo plus best supportive caredrug
Placebo will be administrated as specified in the protocol, following the same dose regimen as MRG004A.